Entera Bio Ltd

NASDAQ:ENTX  
1.07
+0.02 (+1.96%)
Regulatory, Other Pre-Announcement

Entera Bio Announces Completion Of Enrollment In Phase 2 Clinical Trial Of EB613 In Osteoporosis

Published: 11/09/2020 14:03 GMT
Entera Bio Ltd. (ENTX) - Entera Bio Ltd Announces Completion of Enrollment in Phase 2 Clinical Trial of Eb613 in Osteoporosis.
Entera Bio - Expects to Report Interim 3 Month Biomarker Data for Enrolled Patients in Q1:21 With Final Bone Mineral Density Data Expected in Q2:21.
Entera Bio Ltd - Believes Its Current Cash Position Will Be Sufficient to Fund Its Operations Into Q2 of 2021.